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Abstract
Benefit package is crucial for implementing universal health coverage (UHC). This editorial analyses how the 
benefit package of the Thai Universal Coverage Scheme (UC Scheme) evolved from an implicit comprehensive 
package which covered all conditions and interventions (with a few exceptions), to additional explicit positive 
lists. In 2002 when the Thai UC Scheme was launched; the comprehensive benefit package, including medicines 
in the national essential list of medicines, formerly offered by the previous schemes were pragmatically adopted. 
Later, when capacities of producing evidence on health technology assessment (HTA) increased, rigorous 
assessment of cost effectiveness is mandatorily required for inclusion of new interventions into the Thai UC 
Scheme benefit package. This contributed to evidence-informed policy decisions. To prevent emptied promises, 
whichever policy choices are made about the benefit package, either using a negative or a positive list, developing 
country governments need to make quality health services available and accessible by the entire population. 
Political decision on benefit package should be informed by evidence on cost effectiveness, equity dimension 
and health system capacity to deliver equitable services. Low- and middle-income countries need to strengthen 
HTA capacity to generate evidence and inform policies.   
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Background 
Decision-making about the benefit package is a key entry 
point in implementing universal health coverage (UHC). 
Several prioritizing criteria are used such as burden of disease, 
cost-effectiveness of interventions, budget impact, equity1 
and capacities of health systems to deliver. However, it is the 
political decisions, within the government fiscal capacity, at 
the end.2,3 
Most OECD countries apply a positive list of medicines in 
their benefit package but there is no clear pattern of applying 
positive or negative lists for medical interventions.4 Thailand, 
however initially applied an implicit benefit package with a 
negative list but is now expanding the number of items in 
the positive list, ascertained through rigorous reviews using 
health technology assessments (HTAs) and other concerns.
Thai populations are covered by three public health 
insurance schemes since 2002. The civil servants and the 
pensioners, including their dependants (parents, spouses 
and children below 20 years old) are covered by the Civil 
Servant Medical Benefit Scheme (CSMBS). This scheme is 
financed solely by annual budget allocation and managed 
by Comptroller General’s Department of the Ministry of 
Finance. Private sector employees are mandatorily covered 
by Social Health Insurance (SHI) which is managed by Social 
Security Office, Ministry of Labour.5 The sources of finance 
come from equal contributions by employees, employers and 
the government.
The remaining populations are covered by the Universal 
Coverage Scheme (UC Scheme) which is financed by the 
government annual budget and managed by the National 
Health Security Office (NHSO). The latest national Health 
and Welfare Survey 2017 reported 99.2% population coverage 
by insurance schemes6; of which 75.7% by UC Scheme, 17.2% 
by SHI and 7.1% by CSMBS. 
Given the comprehensive benefit package and minimum 
copayment at point of service by all three public insurance 
schemes, the data from World Development Indicators shows 
that the out-of-pocket payments by households had reduced 
from 34.2% of current health expenditure in 2000 to 12.1% 
in 2016.7 Domestic general government health expenditure 
increased from 13% to 15.3% of total government expenditure 
in the same period. This has resulted in low prevalence of 
catastrophic health spending and health impoverishment, 
a high level of UHC index, and a low level of unmet health 
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needs.8 This is the result of increased government spending 
on health; and a comprehensive benefit package; with literally 
zero copayment.
These favourable achievements are gained despite the 
turbulent political climate and protracted political conflicts.9 
Between 2001 and 2018, the UC Scheme thrived eight rival 
governments, six elections, two coup d’états and 13 health 
ministers.10 This reflects that UC Scheme is gradually 
owned by the people who had benefited from it; not by the 
political party who initiated it. Despite the decline in gross 
domestic products (GDP) growth (-0.7% in 2009), the UC 
Scheme budget had increased, reflecting sustained political 
and financial commitment across governments (see Figure). 
In addition, the extensive geographical coverage of primary 
healthcare and referral to secondary and tertiary hospital 
care are the core implementation platform, which results in 
favourable UHC outcomes. 
This editorial analyzes and discusses how the benefit 
package applied by the UC Scheme evolved from an implicit 
package where all conditions and interventions were covered, 
except for a few in the negative list, to an application of and 
increased number in the positive list in recent years. 
Benefit Package of UC Scheme: Analysis of Historical 
Evolution 
Pragmatic Approach: Comprehensive Package With a 
Negative List 
Prior to UHC in 2002, there were four insurance schemes 
covered 70% of population. These were: (1) the Medical 
Welfare Scheme for the low-income, the elderly, children 
under 12 years and disabled people; (2) the voluntary health 
insurance scheme for non-poor households; (3) the CSMBS; 
and (4) the SHI. Historically, the benefit package offered by 
these four schemes was comprehensive, covering outpatient 
and inpatient services, accidents and emergencies; all included 
medicines in the National List of Essential Medicines (NLEM). 
There were a few items in the negative list such as aesthetic 
surgery, treatment of infertility and transgender operations. 
Some health promotion interventions were provided by 
Ministry of Public Health.
At the 2002 reform, the UC Scheme combined the Medical 
Welfare Scheme, the voluntary insurance and included the 
30% uninsured population. Given the path dependency, it 
continued to apply a comprehensive benefit package, with a 
few items in the negative list including antiretroviral treatment 
for HIV and treatment of end-stage renal failure due to high 
costs and health system inability to equitably deliver services. 
This comprehensive package also covered health promotion 
and disease prevention services for the whole population.
Analysis showed that two drivers influenced the adoption 
of a comprehensive package with a negative list for the UC 
Scheme. Firstly, UHC was a political manifesto at the January 
2001 election, and needed to be achieved in a year. Thailand 
did not have the capacity for a thorough HTA and time did not 
allow for an extensive assessment about what interventions 
should be covered. At the 2002 reform, there were no 
discussions on what the basic minimum package should look 
like and what the costs of delivering these services should be. 
Secondly, taking out non cost-effective services, previously 
provided by Medical Welfare Scheme and voluntary 
health insurance, was politically unpalatable and socially 
unacceptable. It took one year following the January 2001 
election to achieve nationwide coverage by UC Scheme, with 
a pragmatic application of a negative list for health services. 
Pharmaceutical Benefit: Explicit Positive List of National 
Essential Medicines 
The UC Scheme applies a positive list for pharmaceutical 
Figure. Requested and Approved Per Capita Budget of UC Scheme, and Annual GDP Growth, 2002-2017. Abbreviations: GDP, gross domestic products; US, 
Universal Coverage.
Source: Authors’ synthesis from NHSO annual reports on budget request and approval; and GDP growth from World Development Indicators. 
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benefits, which covers all medicines in the NLEM. Medicines 
outside the NLEM are also covered if clinically indicated. 
The NLEM is subjected to regularly reviews based on health 
needs, safety, efficacy, cost-effectiveness, budget impact and 
affordability. The review requires all national experts in the 
22 therapeutic groups to declare conflicts of interest to ensure 
transparency and objectivity. 
The Health Economics Working Group, tasked by the NLEM 
sub-committee, generates evidences on cost effectiveness-
-with reference to a cost-effectiveness threshold of 160 000 
Thai Baht (US$ 5333; exchange rate 30 Baht per US$) for 
one quality adjusted life year gained,11 budget impact, equity 
and delivery capacities, while the Price Negotiation Working 
Group negotiates for the lowest possible prices. When the 
price reaches the threshold, and if the budget impact is large, 
the price will be further negotiated. Thailand also applied 
government uses licenses to improve access to life saving 
medicines12 despite political pressure from the US government 
and European Commission to apply other mechanisms.13 
In 2004, the NLEM moved from a minimum list to a 
reimbursement list of 692 active pharmaceutical ingredients. 
In 2008, the NLEM covered high-cost specialized medicines 
where patients could access them through an authorization 
system by specialists in the field. Anticancer, antiplatelet, 
drug effecting immune response and drug for genetic 
disorders, orphan medicines and antidotes were added to 
the NLEM in 201014; A study shows it has improved access 
to these medicines.15 The current 2019 NLEM consists of 857 
medicines. The number of items in the Thailand’s NLEM is 
close to that of World Health Organization (WHO) model list 
of essential medicines (see Table). 
From Implicit to Explicit High-Cost Interventions 
Recognizing challenges of access to certain high-cost 
interventions both within and outside the implicit benefit 
package, the Benefit Package sub-committee of the National 
Health Security Board (NHSB) gradually approved 
interventions (both services and medicines) and published 
them in the Royal Gazette and NHSB’s order as a positive list.8
High cost and new interventions were gradually added 
to the benefit package, for example, universal antiretroviral 
treatment (including voluntary counselling and testing, CD4 
monitoring, viral load test and condom promotion) in 2006 
and ‘detect and treat’ policy for any CD4 counts in 2016; renal 
replacement therapy using Peritoneal Dialysis First policy in 
200916; seasonal influenza vaccination for high risk groups in 
2009; treatment of chronic kidney diseases to prevent clinical 
progression towards end-stage renal failure in 2011; liver 
transplantation for hepatic failure patients below 18 years old 
in 2011.
Table. NLEM 2019, Compared With WHO Model List of Essential Medicines, March 2017
Group Drug Group Items in WHO Model List of Essential Medicines (2017) Items in NLEM of Thailand (2019)
1 Anaesthesia 14 9
2 Medicine for pain and palliative care 22 20
3 Antiallergics and medicines used in anaphylaxis 5 4
4 Antidotes and other substances used in poisonings 15 12
5 Anticonvulsants/antiepileptics 11 10
6 Anti-infective medicines 153 100
7 Antimigraine medicines 4 4
8 Antineoplastic and immunosuppressives 53 44
9 Antiparkinson medicines 2 1
10 Medicines effecting the blood 16 13
11 Blood products of human origin and plasma substitutes 12 12
12 Cardiovascular medicines 30 30
13 Dermatological medicines 18 13
14 Diagnostic agents 7 2
15 Disinfectants and antiseptics 7 7
16 Diuretics 5 5
17 Gastrointestinal medicines 11 11
18 Hormones, other endocrine medicines and contraceptives 31 22
19 Immunological 24 14
20 Muscle relaxants and cholinesterase inhibitor 6 5
21 Ophthalmological preparations 16 11
22 Oxytocin and antioxytotic 5 5
23 Peritoneal dialysis solution 1 1
24 Medicine for mental and behavioral disorders 17 15
25 Medicines acting on the respiratory tract 6 6
26 Solutions correcting water, electrolyte and acid-base disturbances 9 8
27 Vitamins and minerals 12 9
28 Ear, nose, and throat medicines 4 3
29 Specific medicines for neonatal care 6 4
30 Medicines for disease of joints 8 8
Abbreviations: NLEM, National List of Essential Medicines; WHO, World Health Organization.
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Inclusions of these interventions in the positive list of the 
UC Scheme’s benefit package are also subject to a rigorous 
assessment by several criteria including HTA, budget impact, 
equity, supply-side capacity and catastrophic impact to the 
patients or households. These complex multi-dimensional 
criteria for coverage decisions contributed to evidence-
informed political decisions.17 Although renal replacement 
therapy was not cost-effective and had large budgetary impact, 
it was catastrophic to households and created inequity across 
the schemes, as CSMBS and SHI members were covered. The 
political decision taken through the Cabinet Resolution on 
universal renal replacement therapy for the UC Scheme in 
2009 was based on ethical concerns, life saving measures and 
prevention of catastrophe.16
Importantly, the government approved additional budget 
through Cabinet Resolutions for new interventions which 
were not covered by the previous benefit package in order 
to ensure no “unfunded mandates.” If the NHSB singles out 
certain interventions already covered and funded in the 
comprehensive package paid by capitation for outpatient 
services, and Diagnostic Related Group for inpatient services, 
part of the existing budget is earmarked for these interventions 
to improve access.
Discussion 
The Thailand example of benefit package development 
provided a number of useful lessons to low- and middle- 
income countries. 
First, there are two policy choices, either comprehensive 
package with the application of a negative list or application 
of a positive list. Countries applying a positive list should be 
cautious about itemized fee-for-service payments which can 
trigger supplier-induced demand and inefficiencies.18 The 
under-provision of services in the implicit comprehensive 
package can be minimized by clinical audits, and strong 
adherence to clinical practice guidelines.19 Singling out 
certain interventions in the implicit benefit package and apply 
additional incentive can improve access of interventions with 
limited access. 
Whichever policy choices are made, governments need to 
make quality health services available to the entire population 
and subsidize the poor and vulnerable population to prevent 
financial barriers. Adequate funding to UC Scheme through 
full cost subsidies in the capitation payment for outpatient 
services, and Diagnostic Related Group payment for inpatient 
services prevents under-provision of services and is effective 
to prevent balance billing by healthcare providers. 
Second, implicit benefit package with clear negative list 
is more practical as it takes shorter time to develop than 
an evidence-informed positive list provided that a political 
window opens briefly and might not stay open very long.20 
Using HTA in producing a positive list can later fix the gaps 
of access to new interventions, but a secure new budget is 
required to prevent unfunded mandates. 
Third, inclusion of new medicines and interventions to 
the benefit package should be subjected to a rigorous review. 
In addition to cost effectiveness, equity in access and health 
systems readiness to provide new interventions are equally 
important as decisions are not always simple. 
For example, certain cost-effective interventions, such as 
dental root implants, are not covered as these services are 
available only in a few urban centres and that access can be 
inequitable.8 On the contrary, the non-cost–effective renal 
replacement with high budget impact was covered because 
self-payment for dialysis could bankrupt the households. 
Peritoneal Dialysis First policy in 2009 was adopted based 
on equity concern as traveling cost to hemodialysis centers in 
provincial hospital three times a week was prohibitive to rural 
patients. Instead, peritoneal dialysis could be managed at 
home with dialysis solution supplied to the patient’s home.15 
Whichever decision is made, it must be fully informed 
by evidence. Low- and middle-income countries need to 
strengthen its HTA capacities.
Fourth, the inclusion of new medical products and 
technologies to the benefit package, despite being cost 
effectiveness, could lead to imbalance proportion of curative 
and disease prevention and health promotion expenditure 
such as in the case of Thailand during the last 15 years. 
The government should invest more in effective primary 
prevention which yields great health outcomes.21 
Conclusion
In 2002, as influenced by path dependence from previous 
health insurance schemes which offered comprehensive 
benefit package; and limited capacities to generate HTA 
evidence for prioritization of interventions for inclusion and 
exclusion from the benefit package, the UC Scheme applied 
a pragmatic approach using a negative list for health services 
to accommodate political commitment towards achieving full 
population coverage in a year. 
Being aware of limited access to certain high-cost new 
interventions, the NHSO applied a more explicit positive list 
of new interventions with secured new budget or singled out 
some items from the existing benefit package with earmarked 
budget to boost access through additional incentives. 
Prioritizations of interventions are subject to rigorous HTAs 
of (a) cost effectiveness, (b) long term budget impact analysis, 
(c) health systems capacity to deliver new interventions 
equitably, (d) other ethical and equity considerations. 
Acknowledgement
Funding support was provided by Thailand Science Research 
and Innovation (TSRI) Contract No. RTA628000.
Ethical issues
Not applicable.
Competing interests
Authors declare that they have no competing interests. 
Authors’ contributions
VT designed the manuscript. All authors contributed to drafting and revising 
the manuscript, and gave final approval of the version to be published. 
Authors’ affiliations
1International Health Policy Program, Ministry of Public Health, Nonthaburi, 
Thailand. 2National Health Security Office, Bangkok, Thailand.
Tangcharoensathien et al
International Journal of Health Policy and Management, 2020, 9(4), 133–137 137
References
1. Hayati R, Bastani P, Kabir MJ, Kavosi Z, Sobhani G. Scoping 
literature review on the basic health benefit package and its 
determinant criteria. Global Health. 2018;14(1):26. doi:10.1186/
s12992-018-0345-x
2. Kieslich K, Bump JB, Norheim OF, Tantivess S, Littlejohns P. 
Accounting for technical, ethical, and political factors in priority 
setting. Health Syst Reform. 2016;2(1):51-60. doi:10.1080/232886
04.2016.1124169
3. Glassman A, Giedion U, Sakuma Y, Smith PC. Defining a health 
benefits package: what are the necessary processes? Health Syst 
Reform. 2016;2(1):39-50. doi:10.1080/23288604.2016.1124171
4. Paris V. Health benefits plans in OECD countries. Inter-American 
Development Bank; 2015.
5. Tangcharoensathien V, Prakongsai P, Limwattananon S, 
Patcharanarumol W, Jongudomsuk P. From targeting to universality: 
lessons from the health system in Thailand. In: Townsend P, ed. 
Building Decent Societies: Rethinking the Role of Social Security in 
Development. London: Palgrave Macmillan; 2009:310-322.
6. National Statistical Office, 2017. National Health and Welfare Survey 
2017. https://bit.ly/2EEONiC.  Accessed September 20, 2019.
7. The World Bank. World Development Indicators. https://data.
worldbank.org/data-catalog/world-development-indicators. 
Published 2019. Accessed September 13, 2019.
8. Tangcharoensathien V, Witthayapipopsakul W, Panichkriangkrai 
W, Patcharanarumol W, Mills A. Health systems development in 
Thailand: a solid platform for successful implementation of universal 
health coverage. Lancet. 2018;391(10126):1205-1223. doi:10.1016/
s0140-6736(18)30198-3
9. Tejapira K. The irony of democratization and the decline of royal 
hegemony in Thailand. Southeast Asian Stud. 2016;5(2):219-237. 
doi:10.20495/seas.5.2_219
10. Tangcharoensathien V, Pitayarangsarit S, Patcharanarumol W, et 
al. Promoting universal financial protection: how the Thai universal 
coverage scheme was designed to ensure equity. Health Res Policy 
Syst. 2013;11:25. doi:10.1186/1478-4505-11-25
11. Chaikledkaew U, Kittrongsiri K. Guidelines for health technology 
assessment in Thailand (second edition)--the development process. 
J Med Assoc Thai. 2014;97 Suppl 5:S4-9.
12. Mohara A, Yamabhai I, Chaisiri K, Tantivess S, Teerawattananon 
Y. Impact of the introduction of government use licenses on the 
drug expenditure on seven medicines in Thailand. Value Health. 
2012;15(1 Suppl):S95-99. doi:10.1016/j.jval.2011.11.016
13. Wibulpolprasert S, Chokevivat V, Oh C, Yamabhai I. Government 
use licenses in Thailand: The power of evidence, civil movement and 
political leadership. Global Health. 2011;7:32. doi:10.1186/1744-
8603-7-32
14. Suchonwanich N, Wananukul W. Improving access to antidotes and 
antivenoms, Thailand. Bull World Health Organ. 2018;96(12):853-
857. doi:10.2471/blt.18.217075
15. Sruamsiri R, Wagner AK, Ross-Degnan D, et al. Expanding access 
to high-cost medicines through the E2 access program in Thailand: 
effects on utilisation, health outcomes and cost using an interrupted 
time-series analysis. BMJ Open. 2016;6(3):e008671. doi:10.1136/
bmjopen-2015-008671
16. Chuengsaman P, Kasemsup V. PD first policy: Thailand’s response 
to the challenge of meeting the needs of patients with end-stage 
renal disease. Semin Nephrol. 2017;37(3):287-295. doi:10.1016/j.
semnephrol.2017.02.008 
17. Youngkong S, Baltussen R, Tantivess S, Mohara A, Teerawattananon 
Y. Multicriteria decision analysis for including health interventions in 
the universal health coverage benefit package in Thailand. Value 
Health. 2012;15(6):961-970. doi:10.1016/j.jval.2012.06.006
18. Ginsburg PB. Fee-for-service will remain a feature of major payment 
reforms, requiring more changes in Medicare physician payment. 
Health Aff (Millwood). 2012;31(9):1977-1983. doi:10.1377/
hlthaff.2012.0350
19. Velasco-Garrido M, Schreyögg J, Stargardt, Busse R. Identification 
of health baskets in nine EU countries. Rev Fr Aff Soc. 2006;6:63-
88.
20. Guldbrandsson K, Fossum B. An exploration of the theoretical 
concepts policy windows and policy entrepreneurs at the Swedish 
public health arena. Health Promot Int. 2009;24(4):434-444. 
doi:10.1093/heapro/dap033
21. Musgrove P, Fox-Rushby J. Cost-effectiveness analysis for priority 
setting. In: Jamison DT, Breman JG, Measham AR, et al, eds. 
Disease Control Priorities in Developing Countries. 2nd ed. New 
York: Oxford University Press; 2006:271-285.
